Pyrovalerone Analogues and Therapeutic Uses Thereof
申请人:Butler David
公开号:US20080234498A1
公开(公告)日:2008-09-25
New compounds that bind to monoamine transporters are described. The compounds of the present invention can be racemic or pure R— or S-enantiomers. Certain preferred compounds of the present invention have a high selectively dopamine transporter versus the serotonin transporter. Preferred monoamine transporters for the practice of the present invention include the dopamine transporter, the serotonin transporter and the norepinephrine transporter.
[EN] PYROVALERONE ANALOGS AND THERAPEUTIC USES THEREOF<br/>[FR] ANALOGUES DE PYROVALERONE ET UTILISATIONS THERAPEUTIQUES
申请人:HARVARD COLLEGE
公开号:WO2005034878A2
公开(公告)日:2005-04-21
New compounds that bind to monoamine transporters are described. The compounds of the present invention can be racemic or pure R-or S-enantiomers. Certain preferred compounds of the present invention have a high selectively dopamine transporter versus the serotonin transporter. Preferred monoamine transporters for the practice of the present invention include the dopamine transporter, the serotonin transporter and the norepinephrine transporter.
1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) Analogues: A Promising Class of Monoamine Uptake Inhibitors
作者:Peter C. Meltzer、David Butler、Jeffrey R. Deschamps、Bertha K. Madras
DOI:10.1021/jm050797a
日期:2006.2.1
a search for medications for cocaine abuse. Herein we describe the synthesis and biologicalevaluation of an array of 2-aminopentanophenones. This array has yielded selective inhibitors of the dopamine and norepinephrinetransporters with little effect upon serotonin trafficking. A subset of compounds had no significant affinity at 5HT1A, 5HT1B, 5HT1C, D1, D2, or D3 receptors. The lead compound, racemic